Corvus Pharmaceuticals, Inc.
CRVS
$13.33
-$0.60-4.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 26.73% | 24.02% | 13.34% | 18.83% | 24.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.27% | 53.53% | 55.99% | 54.99% | 52.04% |
| Operating Income | -60.27% | -53.53% | -55.99% | -54.99% | -52.04% |
| Income Before Tax | -19.93% | -6.69% | 75.47% | 73.47% | -99.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.93% | -6.69% | 75.47% | 73.47% | -99.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.93% | -6.69% | 75.47% | 73.47% | -99.57% |
| EBIT | -60.27% | -53.53% | -55.99% | -54.99% | -52.04% |
| EBITDA | -60.36% | -53.58% | -56.09% | -55.17% | -52.31% |
| EPS Basic | 8.14% | 17.93% | 83.13% | 79.27% | -50.77% |
| Normalized Basic EPS | 8.14% | 17.90% | 83.14% | 79.27% | -50.77% |
| EPS Diluted | 39.16% | 46.53% | 47.91% | 42.49% | -125.78% |
| Normalized Diluted EPS | 9.28% | 18.97% | 82.26% | 78.36% | -52.67% |
| Average Basic Shares Outstanding | 22.18% | 24.99% | 29.49% | 34.12% | 37.82% |
| Average Diluted Shares Outstanding | 20.90% | 23.58% | 30.73% | 35.47% | 39.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |